结合体突变白血病中的R-环积累通过触发转录-复制冲突来赋予对PARP1抑制的敏感性
Zhiyan Silvia Liu1,2, Sayantani Sinha3, Maxwell Bannister2
1Molecular Pharmacology and Therapeutics Graduate Program, Department of Pharmacology, University of Minnesota, Minneapolis, Minnesota.
Cancer research
|November 15, 2023
概括
拼接因子基因的突变导致白血病中的R环积累,使它们对PARP抑制剂敏感. 准R循环通路为这些癌症提供了新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症遗传学 癌症遗传学
背景情况:
- 拼接因子 (SF) 基因突变在骨髓性恶性瘤中很常见.
- SF突变可以改变细胞对DNA损伤和治疗剂的反应.
研究的目的:
- 研究SF突变白血病对PARP抑制剂 (PARPi) 的敏感性.
- 阐明SF突变白血病中PARPi敏感性的潜在机制,重点关注R循环积累和DNA损伤反应途径.
主要方法:
- 对SRSF2-和U2AF1-突变白血病细胞系的分析.
- 评估R环水平和对PARPi治疗反应的DNA损伤.
- 研究PARP1和ATR在SF突变白血病中的作用.
- 在R环中PARP1活性与PARPi灵敏度的相关性.
主要成果:
- 在SRSF2-和U2AF1-突变白血病中,尽管完整的同源重组修复,但对PARPi具有优先敏感性.
- 在SF突变白血病中,R循环积累增加,导致PARP1依赖的DNA损伤和细胞死亡.
- PARPi治疗加剧了R循环积累,导致转录复制碰撞和ATR激活.
- 联合抑制PARPi和ATR增强了SF突变白血病中的DNA损伤和细胞死亡.
- 在R环中的PARP1活性与PARPi灵敏度相关.
结论:
- 由于R循环积累,SF突变白血病对PARP1具有独特的依赖性,使其对PARPi敏感.
- 针对R循环相关途径,包括PARP1和ATR,是SF突变骨髓瘤恶性病的有前途的治疗策略.
- 与R循环相关的PARP1活性可以作为SF基因突变患者PARPi敏感性的预测生物标志物.
相关概念视频
02:37Restarting Stalled Replication Forks
5.8K
DNA replication is initiated at sites containing predefined DNA sequences known as origins of replication. DNA is unwound at these sites by the minichromosome maintenance (MCM) helicase and other factors such as Cdc45 and the associated GINS complex.The unwound single strands are protected by replication protein A (RPA) until DNA polymerase starts synthesizing DNA at the 5’ end of the strand in the same direction as the replication fork. To prevent the replication fork from falling apart,...
5.8K
02:37DNA Damage can Stall the Cell Cycle
9.2K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.2K
01:02Long-patch Base Excision Repair
7.0K
Since the discovery of the two BER pathways, there has been a debate about how a cell chooses one pathway over the other and the factors determining this selection. Numerous in vitro experiments have pointed out multiple determinants for the sub-pathway selection. These are:
7.0K